Previously, serum Cystatin C had been demonstrated to be a biomarker for the early detection AKI in other clinical settings, such as patients with traumatic brain injury, neonates, patients with cardiac surgery, patients with liver, and so on [9,17–20]. The gene discussed is CST3; the disease is acute kidney injury.